Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2019 COVID-19 vaccine phase 2/3 efficacy and safety study
2020-004272-17Phase 2Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Nov 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SCB-2019 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Vaccine efficacy against RT-PCR-confirmed COVID-19 of any severity and Efficacy against RT-PCR-confirmed moderate-to-severe COVID-19. Started Nov 2020; status: completed.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004272-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004272-17.